Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 22, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

457

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 457 matching trials for ALS.

Live ClinicalTrials.gov results.

Active filters: "amyotrophic lateral sclerosis" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: ALS
Interventions: MT-1186; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Phoenix, Arizona • Rogers, Arkansas • San Francisco, California + 18 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ION363, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NUZ-001, Matching placebo; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ALS
Interventions: MT-1186, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 34
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: MT-1186; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more

Conditions: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Tazbentetol; Drug
Lead sponsor: Spinogenix; Industry
Eligibility: 18 Years to 85 Years
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: San Francisco, California • Jacksonville, Florida • Tampa, Florida + 11 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: nL-TARDB-002; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: nL-CHCHD-001; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

Safety Study of Oral Edaravone Administered in Subjects With ALS

HEALEY ALS Platform Trial - Master Protocol

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

HEALEY ALS Platform Trial - Regimen I NUZ-001

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Intermediate-size Patient Population Expanded Access Protocol

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

About this ALS clinical trials directory page